Bladder Cancer Treatment Algorithm, According to Dr. Andrea Apolo

By Oncology Brothers - Last Updated: February 10, 2023

Andrea Apolo, MD, Chief of Bladder Cancer – Genitourinary Malignancy at the National Cancer Institute, shares her approach to treating bladder cancer as the field continues to evolve following the outcomes of phase III trials.

Review the algorithm discussed.

Bladder cancer treatment algorithm

Advanced, Metastatic Kidney Cancer: Favorable and Very Favorable Risk Stratification

Karine Tawagi, MDAdvancements in Oncology | June 12, 2024

Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.

PSMAfore: Informing Future Trials of 177Lu-PSMA-617 Versus Chemotherapy for mCRPC

Karine Tawagi, MDAdvancements in Oncology | June 12, 2024

Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.

Sacituzumab Govitecan Versus Platinum-Based Chemotherapy for Second-Line mUC

Karine Tawagi, MDAdvancements in Oncology | June 13, 2024

Dr. Tawagi provides an update as to when SG or chemotherapy should be preferred for patients who do not respond to EV/pembro.

Utilization of ctDNA in the EV/Pembrolizumab Setting

Karine Tawagi, MDAdvancements in Oncology | June 13, 2024

Dr. Tawagi describes how she is using ctDNA in her practice in the EV/pembro setting, and how frequently she is ordering it.

Treating mUC With Preexisting Neuropathy

Karine Tawagi, MDAdvancements in Oncology | June 13, 2024

Dr. Tawagi explains the treatment options available for patients with metastatic bladder cancer who already have neuropathy.

Bladder Cancer Treatment Algorithm, According to Dr. Andrea Apolo

Related Posts